DOCSLIB.ORG

A Convenient Synthesis of the Side Chain of Loteprednol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Convenient Synthesis of the Side Chain of Loteprednol Steroids 76 (2011) 497–501 CORE Metadata, citation and similar papers at core.ac.uk Provided by IR@NEIST - North East Institute of Science and Technology (CSIR) Contents lists available at ScienceDirect Steroids journal homepage: www.elsevier.com/locate/steroids A convenient synthesis of the side chain of loteprednol etabonate—An ocular soft corticosteroid from 20-oxopregnanes using metal-mediated halogenation as a key reaction Pritish Chowdhury ∗, Juri Moni Borah, Papori Goswami 1, Archana Moni Das Natural Products Chemistry Division, North East Institute of Science & Technology, Jorhat 785 006, Assam, India article info abstract Article history: A facile synthesis of the side chain of loteprednol etabonate, namely, chloromethyl-17␣-[(ethoxy- Received 23 August 2010 carbonyl))oxy]-11␤-hydro of loteprednol etabonate, viz., chloromethyl-17␣-[(ethoxycarbonyl))oxy]- Received in revised form 11xy-3-oxoandrosta-1,4-diene-17␤-carboxylate – an ocular soft corticosteroid, has been described start- 23 December 2010 ing from a 20-oxopregnane, namely, 3␤-acetoxy-pregn-5(6),16(17)-diene-20-one (16-dehydropregne- Accepted 17 January 2011 nolone acetate, i.e., 16-DPA) using our recently developed metal-mediated halogenation as a key reaction. Available online 26 January 2011 © 2011 Elsevier Inc. All rights reserved. Keywords: Loteprednol etabonate Soft corticosteroid 16-DPA Metal mediated halogenation Anti-inflammatory agents Corticosteroids have demonstrated excellent anti-inflammatory In loteprednol etabonate, a metabolically labile ester function activity in clinical practice. However, their therapeutic effects are occupies a 17␤-position, while a stable carbonate group occu- often accompanied by toxicity [1]. Hence, the search for improved pies the 17␣-position. The ester is hydrolysed to an inactive topical corticosteroids with less toxicity has been a major goal in carboxylic acid, 1-cortienic acid etabonate, and then into 1- pharmaceutical research and development in recent years. Bodor cortienic acid in biological systems [9–14]. As a result of the and his coworkers [2–4] introduced the concept of ‘soft drug’ by predictable conversion of loteprednol etabonate into an inactive means of designing pharmaceutical agents of reduced toxicity metabolite in the eye following topical administration, this cor- with structural modification to achieve a satisfactory therapeutic ticosteroid has a low propensity for undesirable toxicity while index [5–10]. ‘Loteprednol etabonate’, namely, chloromethyl possessing increased anti-inflammatory activity. In fact, this drug 17␣-[(ethoxycarbonyl))oxy]-11␤-hydroxy-3-oxoandrosta-1,4- has been found to be 1.5 times more potent than the parent anti- diene-17␤-carboxylate 1, which has recently been marketed as an inflammatory agent dexamethasone. Clinical trials on these drugs ocular anti-inflammatory agent, is a soft corticosteroid developed are also going on for a safer treatment of gastrointestinal inflam- on the concept of Bodor and his group [5–7]. The synthesis of a soft mation [13]. drug is achieved by starting with a known inactive metabolite of a In continuation of our work on steroid transformations [15–21], known drug. The inactive metabolite is then modified to an active we recently introduced a potential method of metal-mediated form that after having achieved its therapeutic role, undergoes halogenation of 20-oxopregnane, namely, 16-DPA and its rela- a predictable and controllable one- or two-step transformation tives using the system MnO2–TMSCl/AcCl–AcOH giving an almost in vivo back to the inactive metabolite via known process of Cl enzymatic deactivation [11,12]. Loteprednol etabonate 1 is one O O 18 20 of the first-generation cortienic acid-based soft corticosteroids to 12 HO 11 O get approved by Food and Drug Administration (FDA) for use in all O 19 13 17 inflammatory and allergy-related ophthalmic disorders [4]. 1 9 16 O 2 14 10 8 15 3 H 7 O 5 ∗ 4 6 Corresponding author. Tel.: +91 376 2370 121x2362; fax: +91 376 2370 011. E-mail address: [email protected] (P. Chowdhury). 1 1 Present address: IIT Guwahati Campus, North Guwahati, India. 0039-128X/$ – see front matter © 2011 Elsevier Inc. All rights reserved. doi:10.1016/j.steroids.2011.01.006 498 P. Chowdhury et al. / Steroids 76 (2011) 497–501 Cl OMe O O O O H Cl i ii iii AcO AcO AcO HO H H H 4 5 2 3 iv OH OAc OAc H H H O v vi HO AcO H AcO H H 8 6 7 vii OAc + H3O H ix O AcO H OAc OAc Cl OH O O O OH OH O O viii O x.xi AcO AcO H H AcO H 11 9 10 Scheme 1. Reagents and conditions: (i) H2, Pd–C, 95%, (ii) MnO2–TMSCl/AcCl–AcOH, 81%, (iii) 3% KOH, MeOH–H2O, 75%, (iv) LiAlH4, THF, 88%, (v) CAN, AcOH, 75%, (vi) m-CPBA, CHCl3, 62%, (vii) H2SO4, acetone–H2O, 48%, (viii) Jones reagent, 57%, (ix) OsO4–H2O2, rt., 50%, (x) NaIO4, Ethyl chloroformate, 70% and (xi) chloromethyl iodide, 75%. quantitative yield of 17␣, 21-dichloro 20-oxo-pregnanes. In the Favorskii rearrangement product 5 was then subjected to metal- present work, using this halogenation as a key reaction, a short mediated reduction by using lithium aluminium hydride (LiAlH4) and convenient method for the construction of the side chain of at room temperature in ether or THF which furnished the alco- loteprednol etabonate 1 has been developed from 20-oxopregnane, hol derivative, pregn-17(20)-ene-3␤, 21-diol 6 in high yield. The namely, 3␤-acetoxy-pregn-5(6),16(17)-diene-20-one (16-DPA) 2, compound 6 was acetylated by the newly reported method [19] which is readily available in the laboratory and therefore, in acetic acid in the presence of ceric ammonium nitrate (CAN) to had been taken as the model starting material (Scheme 1) obtain the acetylated product, 3␤, 21-diacetoxy-pregn-17(20)-ene [18]. 7 in quantitative yield. 16-DPA 2 was hydrogenated by Pd/C to form 3␤-acetoxy- Compound 7 was then epoxidised with m-chloroperbenzoic 5␣-pregnan-20-one 3 in quantitative yield and was subjected to acid (m-CPBA) which, after purification by preparative thin chlorination using our reagent system MnO2–TMSCl/AcCl–AcOH layer chromatography (TLC) furnished two isomeric epoxides, to give 17␣, 21-dichloro-3␤-acetoxy-5␣-pregnan-20-one 4 in very 3␤, 21-diacetoxy-17␣,20␣-epoxy-5␣-pregnane 8a and 3␤,21- high yield. diacetoxy-17␤,20␤-epoxy-5␣-pregnane 8b. The mass spectrum of Favorskii rearrangement of the compound 4, under mild basic both the products showed a molecular ion peak at 418 (M+) and condition with 3% KOH in methanol–water (85:15) followed in 1H NMR spectrum, both showed a multiplet at near 3.0 ppm for by concomitant deacetylation of 3␤-acetoxy group furnished C-20 proton under the epoxide ring. 17(20)-20-methoxycarbonyl derivative, namely, pregn-17(20)- The major epoxide 8a was assigned to have a 17␣- ene-3␤-ol-21-oic acid methyl ester 5 also in almost quantitative orientation because of its favourable formation due to the yield [15,16]. steric factor [22–24] associated with the steroid molecule and P. Chowdhury et al. / Steroids 76 (2011) 497–501 499 hence the minor epoxide 8b was assigned to have a 17␤- 5␣-pregnan-3␤,17␣, 21-triol-20-one 12. The compound exhibited orientation. the molecular ion peak at 350(M+). The IR spectrum exhibited a OAc OAc broad band at 3300–3400 cm−1 for the three hydroxyl groups and H H another at 1710 cm−1 for the C-20 carbonyl group present in the O O molecule. OH O OH AcO AcO H H 8a 8b HO Acid-induced epoxide ring opening reaction was carried out on H the major epoxide 8a to get the desired compound 9 witha17␣- 12 hydroxy group. Although perchloric acid is widely used for opening up of an epoxide ring, the use of this acid led to almost complete Conversion of compound 10 to get the requisite side chain of hydrolysis of C-3 and C-21 acetate groups of the compound 8a loteprednol etabonate 1 is well known [6], which involves the peri- giving poor yield of the desired diol 3␤, 21-diacetoxy-5␣-pregnan- odic acid oxidation cum degradation with sodium metaperiodate to 17␣, 20-diol 9, even when the acid was used in low concentration. cortienic acid derivative followed by carboxylation of 17␣-hydroxy The use of sulphuric acid in aqueous acetone was used as a group with ethyl chloroformate and the esterification of 17␤- reagent of choice because of the fact that it does not affect hydrol- carboxylic acid with chloromethyl iodide. These steps provide the ysis of the acetate groups present in a steroid molecule [25] which desired 17␤-ester functionality and 17␣-carbonate functionality is desirable in this case for the future operation and also would fur- present in loteprednol etabonate and related drugs. nish the diol 9 having the requisite 17␣-orientation of the hydroxyl Thus the present methodology paves a useful way to con- group from the ␣-epoxide 8a, irrespective of cis or trans opening struct the side chain of loteprednol etabonate – an ocular due to preferential nucleophilic attack on its C-20 carbon atom as soft corticosteroid directly from 20-oxopregnanes via its C- depicted in Scheme 1. Thus, when this epoxide was treated with a 21 functionalisation in a much simpler and easier way with small amount of concentrated sulphuric acid in aqueous acetone, this newly developed metal-mediated halogenation technique it yielded the desired compound, 3␤,21-diacetoxy-5␣-pregnan- which avoids harsh and tedious reaction conditions [33–36] 17␣,20-diol 9 in good yield. The mass spectrum of the product after associated with this conversion.
Load more

Recommended publications
  • A Convenient Synthesis of the Side Chain of Loteprednol
    Steroids 76 (2011) 497–501 Contents lists available at ScienceDirect Steroids journal homepage: www.elsevier.com/locate/steroids A convenient synthesis of the side chain of loteprednol etabonate—An ocular soft corticosteroid from 20-oxopregnanes using metal-mediated halogenation as a key reaction Pritish Chowdhury ∗, Juri Moni Borah, Papori Goswami 1, Archana Moni Das Natural Products Chemistry Division, North East Institute of Science & Technology, Jorhat 785 006, Assam, India article info abstract Article history: A facile synthesis of the side chain of loteprednol etabonate, namely, chloromethyl-17␣-[(ethoxy- Received 23 August 2010 carbonyl))oxy]-11␤-hydro of loteprednol etabonate, viz., chloromethyl-17␣-[(ethoxycarbonyl))oxy]- Received in revised form 11xy-3-oxoandrosta-1,4-diene-17␤-carboxylate – an ocular soft corticosteroid, has been described start- 23 December 2010 ing from a 20-oxopregnane, namely, 3␤-acetoxy-pregn-5(6),16(17)-diene-20-one (16-dehydropregne- Accepted 17 January 2011 nolone acetate, i.e., 16-DPA) using our recently developed metal-mediated halogenation as a key reaction. Available online 26 January 2011 © 2011 Elsevier Inc. All rights reserved. Keywords: Loteprednol etabonate Soft corticosteroid 16-DPA Metal mediated halogenation Anti-inflammatory agents Corticosteroids have demonstrated excellent anti-inflammatory In loteprednol etabonate, a metabolically labile ester function activity in clinical practice. However, their therapeutic effects are occupies a 17␤-position, while a stable carbonate group occu- often accompanied by toxicity [1]. Hence, the search for improved pies the 17␣-position. The ester is hydrolysed to an inactive topical corticosteroids with less toxicity has been a major goal in carboxylic acid, 1-cortienic acid etabonate, and then into 1- pharmaceutical research and development in recent years.
    [Show full text]
  • ABSTRACT This Material Provides Documentation for Users of the Micro-Data Files of the 2000 National Hospital Ambulatory Medical
    2000 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 1 ABSTRACT This material provides documentation for users of the micro-data files of the 2000 National Hospital Ambulatory Medical Care Survey (NHAMCS). The NHAMCS is a national probability sample survey of visits to hospital outpatient and emergency departments, conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. The survey is a component of the National Health Care Survey, which measures health care utilization across a variety of health care providers. There are two micro-data files produced from the NHAMCS, one for outpatient department records and one for emergency department records. Section I of this documentation, “Description of the National Hospital Ambulatory Medical Care Survey,” includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, and population estimates. Section II provides detailed descriptions of the contents of each file’s data record by location. Section III contains marginal data for selected items on each file. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record forms, and lists of codes used in the survey. PAGE 2 2000 NHAMCS MICRO-DATA FILE DOCUMENTATION THIS PAGE HAS BEEN LEFT BLANK INTENTIONALLY. 2000 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 3 Table of Contents Page I. Description of the National Hospital Ambulatory Medical Care Survey A. Introduction ..........................................................5
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (INN) for Pharmaceutical Substances Names for Radicals, Groups & Others
    WHO/PSM/QSM/2007.1 International Nonproprietary Names (INN) for pharmaceutical substances Names for radicals, groups & others comprehensive list 2007 International Nonproprietary Names (INN) Programme Quality Assurance and Safety: Medicines Medicines Policy and Standards WHO/PSM/QSM/2007.1 International Nonproprietary Names (INN) for pharmaceutical substances Names for radicals, groups & others comprehensive list 2007 International Nonproprietary Names (INN) Programme Quality Assurance and Safety: Medicines Medicines Policy and Standards International Nonproprietary Names (INN) for pharmaceutical substances. Names for radicals, groups & others : comprehensive list © World Health Organization 2007 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Recent Advances in the Design and Development of Soft Drugs
    REVIEW Diabetes Research Institute1 and Department of Molecular and Cellular Pharmacology2, University of Miami, Miami, FL, USA and Center for Drug Discovery3, University of Florida, Gainesville, FL, USA Recent advances in the design and development of soft drugs P. Buchwald 1,2, N. Bodor 3 Received November 4, 2013, accepted November 29, 2013 Prof. Dr. Nicholas Bodor, Center for Drug Discovery, University of Florida, Health Science Center, P.O. Box 100497, Gainesville, FL 32610-0497, USA [email protected] Pharmazie 69: 403–413 (2014) doi: 10.1691/ph.2014.3911R This paper summarizes recent developments in the field of soft drug development as collected and reviewed for the 9th Retrometabolism-Based Drug Design and Targeting Conference. Soft drugs are still often con- fused with prodrugs because they both require metabolic transformations; however, they are conceptual opposites: whereas, prodrugs are pharmacologically inactive and are converted by a predictable mecha- nism to the active drug, soft drugs are active therapeutic agents as such and are designed to undergo a predictable and controllable metabolic deactivation after exerting their desired therapeutic effect. Several rationally designed soft drug examples including clinically approved ones (e.g., clevidipine, esmolol, lan- diolol, loteprednol etabonate, and remifentanil) as well as others that have reached clinical investigations within different therapeutic areas (e.g., budiodarone, naronapride, remimazolam, tecarfarine) are briefly summarized. Anesthesiology, which requires a high degree of pharmacologic control during the surgical procedure to maintain the anesthetic state together with a quick return to responsiveness at the end of this procedure, is a particularly well-suited area for soft drug development.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Council Regulation (EC)
    Status: This is the original version (as it was originally adopted). Council Regulation (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, Having regard to the Treaty establishing the European Community, and in particular Article 133 thereof, Having regard to the proposal from the Commission, Whereas: (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty-free treatment should be granted to pharmaceutical products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated intermediates used for the production and manufacture of finished products. (2) The results of the discussions, as set out in the record of discussions, were incorporated into the tariff schedules of the participants, annexed to the Marrakesh Protocol to the GATT 1994.
    [Show full text]
  • Martindale the Complete Drug Reference
    Martindale The Complete Drug Reference Thirty-sixth edition Edited by Sean C Sweetman BPharm, FRPharmS London • Chicago Published by the Pharmaceutical Press An imprint of RPS Publishing 1 Lambeth High Street, London SEl 7JN, UK 100 South Atkinson Road, Suite 200, Grayslake, IL 60030-7820, USA © Pharmaceutical Press 2009 is a trade mark of RPS Publishing RPS Publishing is the publishing organisation of the Royal Pharmaceutical Society of Great Britain First edition of Martindale: The Extra Pharmacopoeia was published in 1883. Squire’s Companion was incorporated in the twenty-third edition in 1952. Thirty-sixth edition published 2009 Printed in China by Everbest Printing Co. Ltd ISBN 978 0 85369 840 1 ISSN 0263-5364 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the prior written permission of the copyright holder. The publisher makes no representation, express or implied, with regard to the accuracy of the information contained in this book and cannot accept any legal responsibility or liability for any errors or omissions that may be made. A catalogue record for this book is available from the British Library Martindale: The Complete Drug Reference Editor: Sean C Sweetman, BPharm, FRPharmS Senior Assistant Editor: Paul S Blake, BPharm, GradDipHealthInformatics, FRPharmS Assistant Editors: Alison Brayfield, BPharm, MRPharmS Julie M McGlashan, BPharm, DipInfSc, MRPharmS Gail C Neathercoat, BSc, MRPharmS Anne V Parsons, BPharm, MRPharmS
    [Show full text]
  • Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin
    Hussey et al. BMC Pharmacology and Toxicology 2013, 14:25 http://www.biomedcentral.com/2050-6511/14/25 RESEARCH ARTICLE Open Access Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus Elizabeth K Hussey1, Anita Kapur1*, Robin O’Connor-Semmes1, Wenli Tao1, Bryan Rafferty1ˆ, Joseph W Polli1, Charles D James Jr2 and Robert L Dobbins1 Abstract Background: The sodium-dependent glucose co-transporter-2 (SGLT2) is expressed in absorptive epithelia of the renal tubules. Remogliflozin etabonate (RE) is the prodrug of remogliflozin, the active entity that inhibits SGLT2. An inhibitor of this pathway would enhance urinary glucose excretion (UGE), and potentially improve plasma glucose concentrations in diabetic patients. RE is intended for use for the treatment of type 2 diabetes mellitus (T2DM) as monotherapy and in combination with existing therapies. Metformin, a dimethylbiguanide, is an effective oral antihyperglycemic agent widely used for the treatment of T2DM. Methods: This was a randomized, open-label, repeat-dose, two-sequence, cross-over study in 13 subjects with T2DM. Subjects were randomized to one of two treatment sequences in which they received either metformin alone, RE alone, or both over three, 3-day treatment periods separated by two non-treatment intervals of variable duration. On the evening before each treatment period, subjects were admitted and confined to the clinical site for the duration of the 3-day treatment period. Pharmacokinetic, pharmacodynamic (urine glucose and fasting plasma glucose), and safety (adverse events, vital signs, ECG, clinical laboratory parameters including lactic acid) assessments were performed at check-in and throughout the treatment periods.
    [Show full text]
  • (INN) for Pharmaceutical Substances Names for Radicals, Groups & Others
    WHO/EMP/QSM/2012.2 International Nonproprietary Names (INN) for pharmaceutical substances Names for radicals, groups & others Comprehensive list 2012 International Nonproprietary Names (INN) Programme Quality and Safety: Medicines Essential Medicines and Health Products WHO/EMP/QSM/2012.2 International Nonproprietary Names (INN) for pharmaceutical substances Names for radicals, groups & others Comprehensive list 2012 International Nonproprietary Names (INN) Programme Quality and Safety: Medicines Essential Medicines and Health Products International Nonproprietary Names (INN) for pharmaceutical substances. Names for radicals, groups & others: comprehensive list © World Health Organization 2012 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e- mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Regulation (EU) No 1238/2010 of the European Parliament
    L 348/36 EN Official Journal of the European Union 31.12.2010 REGULATION (EU) No 1238/2010 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending Annex I to Council Regulation (EEC) No 2658/87 as regards the provision of duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE intermediates used for the production and manufacture EUROPEAN UNION, of finished pharmaceuticals have been granted duty-free treatment, that some of those intermediates have been transferred to the list of INNs, and that the list of Having regard to the Treaty on the Functioning of the European specified prefixes and suffixes for salts, esters or Union, and in particular Article 207 thereof, hydrates of INNs has been expanded. Having regard to the proposal from the European Commission, (5) A fourth review was deemed appropriate and was launched in 2009. It concluded that a certain number of additional INNs and pharmaceutical intermediates used After transmission of the draft legislative act to the national for the production and manufacture of finished phar­ parliaments, maceuticals should be granted duty-free treatment, that some of those intermediates already included in the phar­ maceutical sectoral arrangement and its revisions should 1 Acting in accordance with the ordinary legislative procedure ( ), be transferred to the list of INNs, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/EMP/QSM/2011.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2011 WHO/EMP/QSM/2011.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2011 Programme on International Nonproprietary Names (INN) Quality and Safety: Medicines Essential Medicines and Pharmaceutical Policies The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e- mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]